You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 22, 2025

Haleon Us Holdings Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Haleon Us Holdings
International Patents:194
US Patents:8
Tradenames:28
Ingredients:18
NDAs:31

Drugs and US Patents for Haleon Us Holdings

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Haleon Us Holdings ADVIL COLD AND SINUS ibuprofen; pseudoephedrine hydrochloride TABLET;ORAL 019771-001 Sep 19, 1989 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Haleon Us Holdings ADVIL MULTI-SYMPTOM COLD & FLU chlorpheniramine maleate; ibuprofen; phenylephrine hydrochloride TABLET;ORAL 022113-002 Apr 28, 2017 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Haleon Us Holdings ADVIL PM diphenhydramine hydrochloride; ibuprofen CAPSULE;ORAL 021393-001 Dec 21, 2005 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Haleon Us Holdings CHILDREN'S ADVIL ALLERGY SINUS chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride SUSPENSION;ORAL 021587-001 Feb 24, 2004 OTC Yes Yes ⤷  Try for Free ⤷  Try for Free
Haleon Us Holdings FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 OTC Yes Yes 8,147,461 ⤷  Try for Free Y ⤷  Try for Free
Haleon Us Holdings NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-002 May 18, 2009 OTC Yes Yes 8,940,772 ⤷  Try for Free Y ⤷  Try for Free
Haleon Us Holdings NICORETTE (MINT) nicotine polacrilex GUM, CHEWING;BUCCAL 018612-003 Dec 23, 1998 OTC Yes No ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 7 of 7 entries

Expired US Patents for Haleon Us Holdings

Paragraph IV (Patent) Challenges for HALEON US HOLDINGS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 200 mg/38 mg ➤ Subscribe 2016-02-16
➤ Subscribe Gum 2 mg ➤ Subscribe 2013-01-22
➤ Subscribe Capsules 200 mg/30 mg ➤ Subscribe 2004-12-27
➤ Subscribe Capsules 60 mg ➤ Subscribe 2010-09-08
➤ Subscribe Gum 4 mg ➤ Subscribe 2013-01-22

International Patents for Haleon Us Holdings Drugs

CountryPatent NumberEstimated Expiration
Australia 2009243065 ⤷  Try for Free
Canada 2484592 ⤷  Try for Free
European Patent Office 1868731 ⤷  Try for Free
Norway 20044495 ⤷  Try for Free
South Korea 101316637 ⤷  Try for Free
South Korea 20220027194 ⤷  Try for Free
South Korea 20050004845 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration
Showing 1 to 7 of 7 entries

Supplementary Protection Certificates for Haleon Us Holdings Drugs

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
0428642 07C0081 France ⤷  Try for Free PRODUCT NAME: DOCOSANOL; REGISTRATION NO/DATE IN FRANCE: NL 33457 DU 20070821; REGISTRATION NO/DATE AT EEC: 18517 DU 20031114
1519731 132013902182575 Italy ⤷  Try for Free PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
2506844 1890025-8 Sweden ⤷  Try for Free PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
0428642 57/2007 Austria ⤷  Try for Free PRODUCT NAME: DOCOSANOL; NAT. REGISTRATION NO/DATE: 1-27014 20070518; FIRST REGISTRATION: SE 18517 20031114
0129748 98C0042 Belgium ⤷  Try for Free PRODUCT NAME: ORLISTAT; REGISTRATION NO/DATE: EU/1/98/071/001 19980729
1305329 SPC/GB08/026 United Kingdom ⤷  Try for Free PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
2506844 SPC/GB18/020 United Kingdom ⤷  Try for Free PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 7 of 7 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Haleon US Holdings – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, Haleon US Holdings has emerged as a formidable player, carving out a significant niche in the consumer healthcare sector. This comprehensive analysis delves into Haleon's market position, strengths, and strategic insights, offering a detailed look at how the company is navigating the competitive landscape.

Haleon's Market Position

Haleon, formerly known as GSK Consumer Healthcare, has quickly established itself as a global leader in consumer health since its demerger from GSK in July 2022. The company boasts a strong portfolio of category-leading brands, including household names such as Sensodyne, Panadol, Advil, and Centrum[6].

Global Reach and Market Share

Haleon's market presence spans over 100 countries, with a particularly strong foothold in key markets:

  • North America accounts for 38% of its business
  • EMEA & Latin America represent 39%
  • Asia-Pacific contributes 23%[2]

This diverse geographical spread provides Haleon with a robust platform for growth and resilience against regional market fluctuations.

Category Leadership

Haleon has secured leading positions in five global market categories:

  1. Oral Health
  2. Vitamins, Minerals, and Supplements (VMS)
  3. Pain Relief
  4. Respiratory Health
  5. Digestive Health and Other[2]

This category leadership is underpinned by Haleon's portfolio of nine large-scale, multinational Power Brands, complemented by 23 Local Growth Brands that hold iconic status in their respective markets[2].

Haleon's Competitive Strengths

Haleon's success in the competitive pharmaceutical landscape can be attributed to several key strengths:

1. Brand Portfolio

At the heart of Haleon's competitive advantage lies its exceptional portfolio of category-leading brands. These brands have built strong consumer trust and loyalty over time, providing a solid foundation for sustained growth.

2. R&D and Innovation

Haleon has implemented a new R&D/innovation model, focusing on developing products that meet evolving consumer needs. This commitment to innovation helps the company stay ahead of market trends and maintain its competitive edge[6].

3. Deep Human Understanding

One of Haleon's unique strengths is its investment in proprietary assets to generate deep human understanding. This consumer-centric approach informs brand building, innovation, and marketing strategies[7].

4. Trusted Science

Haleon combines its deep human understanding with trusted science, leveraging technical and scientific talent to develop products that truly resonate with consumers[2].

5. Strong Route-to-Market

The company has established a leading route-to-market, particularly in pharmacies. Haleon boasts leadership in Europe and strong partnerships with mass retail and pharmacy chains in the US[6].

6. E-commerce Growth

In the past two years, Haleon has significantly invested in e-commerce, resulting in a two-fold increase in online sales. This growth has been particularly strong in China, where the company has outperformed the market[6].

Strategic Insights

Haleon's strategy is designed to deliver sustainable above-market growth and attractive returns. Let's explore the key elements of this strategy:

1. Increasing Household Penetration

Haleon aims to expand its consumer base by increasing awareness of health conditions and building brand relevance. This approach is particularly crucial in emerging markets, where there are significant penetration opportunities[3].

2. Capitalizing on New and Emerging Opportunities

The company is well-positioned to meet the growing demand for self-care products. By staying attuned to emerging trends and unmet consumer needs, Haleon can develop innovative solutions that capture new market segments[3].

3. Maintaining Strong Execution and Financial Discipline

Haleon's strategy emphasizes operational excellence and financial prudence. The company aims to deliver:

  • 4-6% annual organic revenue growth
  • Sustainable moderate margin expansion
  • High cash conversion
  • Disciplined capital allocation[2]

4. Running a Responsible Business

Haleon recognizes the importance of corporate responsibility in today's business landscape. This strategic pillar ensures that the company's growth is sustainable and aligned with societal expectations[4].

Market Trends and Opportunities

Haleon is well-positioned to capitalize on several long-term macro trends:

  1. Aging Population: As the global population ages, demand for healthcare products is expected to increase.

  2. Premiumization of Consumer Healthcare: Consumers are increasingly willing to pay for high-quality, trusted healthcare products.

  3. Growing Middle Class in Emerging Markets: This demographic shift presents significant growth opportunities for Haleon's products[8].

"The global consumer healthcare market is one of the largest, most resilient and fastest-growing across the consumer staples sector."[2]

Challenges and Future Outlook

While Haleon's position is strong, the company faces several challenges:

  1. Intense Competition: The consumer healthcare market is highly fragmented and competitive, requiring constant innovation and marketing efforts.

  2. Regulatory Environment: As a healthcare company, Haleon must navigate complex regulatory landscapes across its markets.

  3. Economic Pressures: The challenging consumer environment and inflationary pressures may impact consumer spending on healthcare products.

Despite these challenges, Haleon's robust strategy, strong brand portfolio, and focus on innovation position it well for future growth. The company's commitment to understanding consumer needs and leveraging scientific expertise should enable it to maintain its competitive edge in the evolving healthcare landscape.

Key Takeaways

  • Haleon is a global leader in consumer health, with a strong presence in over 100 markets.
  • The company's success is built on a portfolio of category-leading brands and a strategy that combines deep human understanding with trusted science.
  • Haleon's focus on innovation, e-commerce growth, and strategic market penetration positions it well for future growth.
  • The company is well-aligned with long-term market trends, including an aging population and the premiumization of consumer healthcare.
  • While facing challenges such as intense competition and economic pressures, Haleon's robust strategy and strong market position provide a solid foundation for continued success.

FAQs

  1. Q: What are Haleon's main product categories? A: Haleon leads in five global market categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, and Digestive Health and Other.

  2. Q: How does Haleon differentiate itself from competitors? A: Haleon differentiates itself through its combination of deep human understanding and trusted science, strong brand portfolio, and focus on innovation and e-commerce growth.

  3. Q: What are Haleon's growth targets? A: Haleon aims for 4-6% annual organic revenue growth, sustainable moderate margin expansion, and high cash conversion.

  4. Q: How is Haleon addressing the growing trend of e-commerce? A: Haleon has significantly invested in e-commerce, resulting in a two-fold increase in online sales over the past two years, with particularly strong performance in China.

  5. Q: What long-term trends is Haleon positioned to benefit from? A: Haleon is well-positioned to benefit from trends such as an aging population, premiumization of consumer healthcare, and the growing middle class in emerging markets.

Sources cited: [2] https://www.haleon.com/content/dam/haleon/corporate/documents/investors/annual-report-2022/Haleon-2022AR-Strategic-Report.pdf.downloadasset.pdf [3] https://www.haleon.com/who-we-are/strategy [4] https://www.haleon.com/?___psv__p_5265857__t_a_=&bvstate=pg%3A54%2Fct%3Ar [6] https://www.gsk.com/en-gb/media/press-releases/gsk-introduces-haleon-to-investors/ [7] https://www.haleon.com/who-we-are/haleon-at-a-glance [8] https://www.morningstar.com/company-reports/1235965-haleon-fends-off-headwinds-and-reaps-benefits-from-new-launches-and-marketing-campaigns

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.